Ainos, Inc. - warrants (OQ:AIMDW)
Business Focus: N/A
May 07, 2024 08:00 am ET
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
Proceeds for scaling up the company's VELDONA and AI Nose growth initiatives
Mar 08, 2024 04:20 pm ET
Ainos Reports Full Year 2023 Financial Results
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024
Feb 05, 2024 09:00 am ET
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Updated Chemistry, Manufacturing, and Controls and Stability Test fulfill Ainos' development objectives
Feb 01, 2024 08:35 am ET
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today...
Jan 24, 2024 09:00 am ET
Ainos Announces $1.75 Million Follow-On Funding
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.
Jan 02, 2024 09:00 am ET
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA / ACCESSWIRE / January 2, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced that on December 29, 2023, the Company received a written notice from The Nasdaq Stock Market ("Nasdaq"). The notice informed Ainos that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Rule"
Dec 26, 2023 08:00 am ET
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Mass Production Readiness Targeted for 2H 2024Propelling AI Nose Technology Towards Broader Industry Adoption and Advancing the Mission of Digitalizing Smell
Dec 12, 2023 08:00 am ET
Ainos, Inc. Announces Stock Consolidation
SAN DIEGO, CA / ACCESSWIRE / December 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos," or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding shares of common stock on the basis of one (1) new share of common stock for every five (
Nov 28, 2023 08:30 am ET
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) Information
Nov 21, 2023 08:30 am ET
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Data partially fulfills the safety and efficacy hypotheses of one pilot and two Phase II clinical studies
Nov 09, 2023 04:30 pm ET
Ainos Reports Third Quarter 2023 Financial Results
Product Cycle Transition Approaches its Final Stages
Nov 06, 2023 08:00 am ET
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferon
Sep 25, 2023 08:30 am ET
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share
Sep 18, 2023 07:00 am ET
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive Americans
Sep 05, 2023 07:00 am ET
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
First Batch of 300,000 Units to be Fully Delivered in October
Aug 11, 2023 04:30 pm ET
Ainos Reports Second Quarter 2023 Financial Results
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing
Aug 10, 2023 08:00 am ET
Ainos Celebrates First Listing Anniversary on Nasdaq
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipeline
Aug 09, 2023 08:00 am ET
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry Adoption
Jun 27, 2023 08:30 am ET
Ainos Issues Mid-Year Business Update Letter to Shareholders
Company ramping up marketing of VELDONA® Pet and aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by the end of 2023
Jun 20, 2023 08:30 am ET
Ainos Provides Insights Into Its AI Nose Technology
Ainos' AI-Powered Digital Nose Technology to Transform Telehealth and Point-of-Care Testing
Jun 14, 2023 09:00 am ET
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
Five VELDONA® Pet products are now available
Jun 07, 2023 09:00 am ET
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® Pet
May 30, 2023 09:00 am ET
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow
May 17, 2023 04:30 pm ET
Ainos Appoints Amanda Sung as New Chief Financial Officer
Current CFO Celia Wu announces her retirement and transition to consulting role
May 12, 2023 04:15 pm ET
Ainos Reports First Quarter 2023 Financial Results
Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologies
Mar 31, 2023 05:50 pm ET
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
Revenues increased by 3,832% year over year
Mar 21, 2023 07:00 am ET
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
Ainos expands market for VELDONA® low-dose interferon treatment to animal care
Mar 14, 2023 07:00 am ET
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships
Mar 13, 2023 04:30 pm ET
Ainos Announces US$3 Million Convertible Notes Private Placement
SAN DIEGO, CA / ACCESSWIRE / March 13, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has entered into two convertible note purchase agreements, under which the Company has issued and sold two convertible promissory notes (the "Notes") in a principal amount of US$3 million to certain investors.
Jan 23, 2023 07:00 am ET
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships
Jan 17, 2023 07:00 am ET
Ainos Issues 2023 Shareholder Letter
SAN DIEGO, CA / ACCESSWIRE / January 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to provide the following shareholder letter from Ainos' Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien Tsai.
Oct 31, 2022 07:00 am ET
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
Clinical results thus far have shown low-dose oral interferon's promising efficacy as a new treatment or as an alternative to high-dose injectable interferon
Sep 30, 2022 07:00 am ET
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period.
Aug 24, 2022 07:00 am ET
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19.
Aug 17, 2022 08:05 am ET
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has signed a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. (Taiwan) ("Swiss Pharma"). Pursuant to the agreement, Swiss Pharma will test, manufacture, and package the Company's VELDONA "GMP Clinical Batch" and "GMP Commercial
Aug 15, 2022 07:20 am ET
Ainos Reports Second Quarter 2022 Financial Results
SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the second quarter ended June 30, 2022.
Aug 11, 2022 02:12 pm ET
Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the closing of its previously announced underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exe
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.